Which GLP-1 Is Right for Me? Comparing Your Options
Use this side-by-side guide to match the right GLP-1 medication to your health goals, dosing preferences and insurance situation.
GLP-1 drugs like Ozempic, Wegovy and Mounjaro lower blood sugar and curb appetite by mimicking the gut hormone glucagon-like peptide-1. The “right” GLP-1 for you depends on the problem you are treating (diabetes, weight loss or both), how often you want to dose, your insurance coverage and any other health conditions you have. This guide compares every FDA-approved option so you and your provider can make an informed, personalized choice.
- Eight GLP-1 brand names are FDA-approved in the United States as of October 2026: Ozempic, Wegovy, Rybelsus, Victoza, Saxenda, Trulicity, Mounjaro and Zepbound.
- All but Rybelsus are injections, and five of the eight require only one shot per week.
- Wegovy and Zepbound are approved specifically for chronic weight management in people who meet BMI and health criteria set by the FDA.
- Major medical societies prefer weekly GLP-1s with proven heart-disease benefits, such as semaglutide and tirzepatide, for people with type 2 diabetes and cardiovascular risk.
- GLP-1 medications can delay stomach emptying, so tell your anesthesiologist if you are having surgery; users had 11 times higher odds of a “full” stomach on ultrasound in one study (Wolla et al., 2025).
What GLP-1 Medications Are
GLP-1 medications are prescription drugs that copy the action of glucagon-like peptide-1, a hormone your gut releases after you eat. By activating GLP-1 receptors in the pancreas, brain and stomach, they stimulate insulin, reduce appetite and slow gastric emptying. The class covers several molecules including semaglutide, liraglutide, dulaglutide, exenatide and the dual agonist tirzepatide. All brand-name GLP-1s are FDA-approved either for type 2 diabetes, chronic weight management or both.
Because GLP-1 receptors also exist in the heart and blood vessels, some drugs in the class have shown cardiovascular-risk reduction in large outcome trials, a key reason the American Diabetes Association now recommends them early for people with diabetes and heart disease (diabetes.org).
How GLP-1s Help With Blood Sugar and Weight
GLP-1 receptor agonists lower blood glucose by boosting glucose-dependent insulin release and dampening glucagon. They also communicate with appetite centers in the brain to reduce food intake, which is why higher-dose versions lead to significant weight loss.
Delay of stomach emptying: The same mechanism that slows post-meal glucose spikes can leave food in the stomach longer. A 2025 cohort study found fasted surgical patients on a GLP-1 had median gastric volumes of 0.61 mL/kg versus 0.16 mL/kg in non-users (Wolla et al., 2025).
Cardiovascular benefits: Weekly semaglutide, dulaglutide and tirzepatide have each cut major cardiovascular events in outcome trials. Exenatide did not show a statistically significant reduction in the EXSCEL study after adjustment for medication drop-in (Bethel et al., 2020).
Side-by-Side Comparison of FDA-Approved GLP-1s
Use the table below to scan key differences at a glance.
| Brand (molecule) | FDA indication | Dosing | Device | Average placebo-adjusted weight loss in trials |
|---|---|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes, CV risk reduction | 0.25 mg start, up to 2 mg weekly | Single-use pen | -9.6 % body weight at 2 mg (STEP 2) |
| Wegovy (semaglutide) | Chronic weight management | 0.25 mg titrated to 2.4 mg weekly | Single-use pen | -14.9 % body weight (STEP 1) |
| Rybelsus (oral semaglutide) | Type 2 diabetes | 3 mg, 7 mg or 14 mg tablet daily | Tablet | -4.4 % at 14 mg (PIONEER 4) |
| Victoza (liraglutide) | Type 2 diabetes, CV risk reduction | 1.2 mg or 1.8 mg daily | Multi-dose pen | -6.0 % (LEAD 3) |
| Saxenda (liraglutide) | Chronic weight management | Up to 3 mg daily | Multi-dose pen | -8.0 % (SCALE Obesity) |
| Trulicity (dulaglutide) | Type 2 diabetes, CV risk reduction | 0.75 mg to 4.5 mg weekly | Auto-injector | -5.7 % at 1.5 mg (AWARD-11) |
| Mounjaro (tirzepatide) | Type 2 diabetes | 2.5 mg to 15 mg weekly | Auto-injector | -11.9 % at 15 mg (SURPASS-2) |
| Zepbound (tirzepatide) | Chronic weight management | 5 mg to 15 mg weekly | Auto-injector | -20.9 % at 15 mg (SURMOUNT-1) |
Choosing a GLP-1 Based on Your Health Goal
If your priority is weight loss: The two drugs approved specifically for weight management are Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide 5-15 mg). Clinical trials reported average losses of 15 % and 21 % of starting body weight, respectively, when combined with lifestyle changes.
If your priority is heart protection with diabetes: Ozempic, Trulicity and Mounjaro have all reduced major adverse cardiovascular events in people with type 2 diabetes. Your cardiologist may favor one of these for dual glucose and heart benefits.
Needle-free preference or gastroparesis concern: Rybelsus is the only oral GLP-1, taken on an empty stomach with water at least 30 minutes before any food or other meds. Gastric-emptying effects are dose-related but present with both pills and injections (Wolla et al., 2025) (Sen et al., 2024).
For a deeper dive into matching GLP-1s to goals, see deciding on a GLP-1 medication.
Choosing a GLP-1 Based on Format and Dosing Frequency
Weekly injections dominate 2026 prescriptions because they are convenient and have strong data. Ozempic, Wegovy, Trulicity, Mounjaro and Zepbound all require only one shot per week and come in prefilled, hidden-needle pens. Daily injectables and the oral pill may suit people who dislike large weekly titration jumps or need finer dose control.
Cost and Insurance Coverage in 2026
Retail cash prices for brand-name GLP-1s now range from about $936 to $1,349 per month, regardless of dose. Manufacturer savings cards can reduce the cost to as low as $25 a month for eligible commercially insured patients (novo-care.com). Medicare and Medicaid coverage varies by state and plan.
| Drug | 2026 cash price (one month) | Max savings card benefit | Typical insurance requirement |
|---|---|---|---|
| Ozempic | $936 - $998 | $25 copay, 24 months max | Step therapy common |
| Wegovy | $1,349 | $0 for 12 weeks, then $25 | Often requires prior auth |
| Mounjaro | $1,023 | $25 up to 12 pens | Still off-label for obesity |
| Zepbound | $1,023 | $25, no quantity cap | Prior auth with BMI criteria |
| Trulicity | $942 | $25, unlimited | Generally covered for diabetes |
For state-by-state details, see our deep dives on Ozempic cost in 2026, Wegovy cost and Zepbound cost by dose.
What if Brands Are Not Covered?
If insurance denies a brand-name GLP-1 and the cash price is out of reach, some people consider compounded semaglutide or tirzepatide prepared by a 503A pharmacy on an individual prescription. Rx.com weight loss program offers compounded compounded semaglutide from $99 per month and compounded tirzepatide from $149 per month on a 12-month plan, with the online provider visit and shipping included. Compounded GLP-1s are not FDA-approved and are prepared for a patient when the prescriber decides the commercial product does not meet the patient’s medical needs. Always discuss risks and benefits with a licensed provider.
💡 Disclosure
Rx.com sells compounded semaglutide and tirzepatide. Compounded products are not the same as any brand-name medication and have not been evaluated by the FDA for safety, efficacy or potency.
Key Safety and Side Effects to Know
Nausea, fullness and constipation are the most common side effects and usually improve after the first 4-6 weeks (DailyMed). Eating smaller meals, staying hydrated and increasing fiber gradually can help. Serious risks are uncommon but include pancreatitis, gallbladder disease and very rarely intestinal obstruction.
Gastric emptying before surgery: Two prospective ultrasound studies found users had 5- to 11-fold higher odds of retaining food particles despite fasting (Wolla et al., 2025) (Sen et al., 2024). Current anesthesia guidelines recommend withholding weekly GLP-1s for at least one week before elective procedures and flagging daily drugs at the preop visit.
Cardiac implantable devices: Rapid weight loss has been associated with rare lead displacement known as Twiddler syndrome (Seiler et al., 2026). Doctors should monitor device patients closely during significant weight changes.
Still deciding whether to start a GLP-1?
Check the column that fits your situation:
✅ Likely a good candidate
- BMI ≥ 30 or BMI ≥ 27 with a weight-related condition
- Type 2 diabetes not at target on metformin alone
- No history of pancreatitis or medullary thyroid cancer
- Comfortable with injections or daily fasting pill routine
🏥 See a doctor first
- Personal or family history of MEN 2 or MTC thyroid cancer
- Active gallbladder disease or pancreatitis episode
- Severe gastrointestinal disorder like gastroparesis
- Planning surgery within the next week
- Pregnant, breastfeeding or trying to conceive
- Using insulin or sulfonylureas with frequent lows
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Severe, persistent stomach or back pain: could signal pancreatitis.
- Yellowing of the skin or eyes: may indicate gallstones or liver injury.
- Repeated vomiting and inability to keep liquids down: risk of dehydration and kidney injury.
- Signs of low blood sugar such as shaking, confusion or sweating, more likely if you also take insulin or sulfonylureas.
- Difficulty breathing or swelling of the face or throat: possible allergic reaction.
- Severe constipation lasting more than one week despite laxatives.
- Thoughts of self-harm or depression. Call or text the Suicide & Crisis Lifeline at 988 if you or a loved one is in crisis.
Scientific References
- Wolla CD, Pecha TJ, Sirianni JM, et al. Ultrasound assessment of preoperative gastric volume in fasted diabetic surgical patients: A prospective observational cohort study on the effects of glucagon-like peptide-1 agonists on gastric emptying. J Clin Anesth. 2025.
- Bethel MA, Stevens SR, Buse JB, et al. Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation. 2020.
- Sen S, Potnuru PP, Hernandez N, et al. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia. JAMA Surg. 2024.
- Seiler T, Noti F, Laimer M, et al. Semaglutide-associated Twiddler syndrome. JCEM Case Rep. 2026.
- Diabetes Research, Education, Advocacy | ADA. diabetes.org.
- novo-care.com.
- DailyMed. dailymed.nlm.nih.gov.
Frequently Asked Questions
Is one GLP-1 better than the others for weight loss?
Zepbound showed the greatest average weight loss (about 21 % of starting weight at the highest dose) in head-to-head trials, but the “best” drug is the one you can access, tolerate and stay on consistently. Insurance approval, side-effect profile and your medical history all matter more than published averages.
Can I switch from Ozempic to Wegovy if I plateaud?
Yes, both contain semaglutide but Wegovy allows titration up to 2.4 mg weekly, which may overcome a plateau. Your provider will usually have you step up doses again to minimize side effects. Never adjust doses on your own.
Do GLP-1s cause muscle loss?
Rapid weight loss can include lean mass. Eating 0.8-1.2 g of protein per kg body weight and doing resistance exercise helps maintain muscle. Talk to your provider before adding supplements.
How long do I need to stay on a GLP-1?
Obesity and type 2 diabetes are chronic conditions. Stopping the drug often leads to partial or full weight regain and higher A1c within months. Most people stay on therapy long term, with dose adjustments for maintenance.
Will a GLP-1 interact with my other medications?
GLP-1s slow stomach emptying, which can delay absorption of oral drugs such as antibiotics or pain medication. Separate critical meds (like thyroid hormone) by at least four hours, and monitor blood sugar closely if you use insulin or a sulfonylurea.
Can I drink alcohol while on a GLP-1?
Moderate alcohol may worsen nausea and raises the risk of low blood sugar when combined with insulin or certain diabetes pills. Limiting or avoiding alcohol during the dose-escalation phase is safest.
Are there any long-term unknowns?
Most GLP-1s have over a decade of real-world data, but high-dose use for obesity and use in younger populations are newer. Ongoing post-marketing studies are tracking thyroid cancer incidence, pancreatitis rates and long-term cardiovascular outcomes.
